<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is often associated with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001397'>steatosis</z:hpo> of the liver and other organs, as well as <z:hpo ids='HP_0000822'>hypertension</z:hpo>, type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have implicated a number of <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> including cytokines, adipokines and <z:chebi fb="0" ids="23899">eicosanoids</z:chebi> in the <z:mp ids='MP_0001845'>inflammatory responses</z:mp> that accompany the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Measurements of the circulating levels of the inflammatory molecules that accompany this syndrome might provide leads to therapeutic approaches to modulate the <z:mp ids='MP_0001845'>inflammatory responses</z:mp> and thereby alter disease progression </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, we summarize recent studies on classical and newer <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> in the pathogenesis of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in humans and experimental models </plain></SENT>
</text></document>